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Dilated cardiomyopathy in chronic dialysis patients is an independent risk factor for cardiac mortality. Carvedilol has been shown to improve 
mortality and ejection fraction in heart failure pts. But data looking at similar effect in dialysis pts is lacking. We sought to evaluate the effects of 
carvedilol on dilated cardiomyopathy in chronic dialysis patients.
Methods: We retrospectively identified 33 patients on chronic dialysis with low ejection fraction (< 45%) who were initiated on carvedilol or 
switched to carvedilol if they were previously on a different beta blocker. Patients were followed for 2 years and changes in EF, HR, BP, LV end 
systolic and diastolic dimensions, left atrial size, aortic root diameter and LV Mass were noted. Of cohort, 55% were 40-60 years of age, 52% were 
male, 61% were African American, 70% were on ACE/ARB, 61% were previously on a different beta blocker, 45% were on calcium channel blocker, 
49% were on both ACE/ARB and beta blocker, 58% had HTN as cause of renal failure, 67% were on dialysis for > 2 years, 52% had non-ischemic 
cardiomyopathy. Mean duration of follow up in 1st year was 7.4 months; in 2nd year 22 months.
Results: Treatment with carvedilol resulted in a significant improvement in Ejection fraction along with significant reduction in heart rate, systolic 
and diastolic blood pressure.
Conclusion: This study validates the use of carvedilol in all dialysis patients with dilated cardiomyopathy. 
TABLE 1: Blood pressure, Heart Rate and Echocardiographic Parameters (mean ± SEM)
Baseline Within 1 year # Within 2 years #
Heart Rate 83.60 ± 2.18 73.00 ± 2.15 ** 74.56 ± 2.99 *
Systolic Blood Pressure 135.8 ± 4.45 118.6 ± 3.95 ** 119.7 ± 6.52 *
Diastolic Blood Pressure 81.00 ± 3.07 69.04 ± 3.07 ** 68.47 ± 3.70 *
LVEF (%) 31.55 ± 1.71 38.04 ± 2.89 * 44.74 ± 3.31 ***
LVEF (%) prior BB 33.65 ± 2.09 36.63 ± 3.52 41.10 ± 5.08
LVEF (%) BB Naïve 28.31 ± 2.80 40.30 ± 5.16 * 48.78 ± 3.99 ***
LVEDD (mm) 59 ± 1.37 56.12 ± 1.75 55.86 ±1.70
LVEDD (mm) prior BB 59.07 ± 1.70 56.08 ± 2.32 58.43 ± 2.38
LVEDDD (mm) BB Naïve 58.89 ± 2.44 56.20 ± 2.55 53.29 ± 2.24
LVESD (mm) 45.88 ± 1.60 40.82 ± 1.97 * 41.29 ± 2.35
LVESD (mm) prior BB 46.20 ± 1.74 40.75 ± 2.46 43.86 ± 3.87
LVESD (mm) BB Naïve 45.33 ± 3.30 41.00 ± 3.55 38.71 ± 2.62
LV mass (gm) 402 ± 26.75 389.1 ± 40.34 377.8 ± 31.17
Left Atrium (mm) 43.83 ± 1.73 44.35 ± 1.66 43.00 ± 1.78
Aortic Root (mm) 33.5 ± 1.46 33.65 ± 1.75 32.38 ± 0.85
Interventricular Septum 13.22 ± 0.60 13.44 ± 0.516 12.77 ± 0.54
LV Posterior Wall 13.07 ± 0.52 12.88 ± 0.58 12.62 ± 0.41
* p< 0.05 compared to baseline LVEF = left ventricular ejection fraction
** p< 0.01 compared to baseline LVEDD = left ventricular end diastolic dimension
*** p < 0.0005 Compared to baseline LVESD = left ventricular end systolic dimension
BB = beta blocker
#Mean time interval between baseline and follow up echocardiogram within 1 year: 7.4 months
#Mean time interval between baseline and follow up echocardiogram within 2 year: 22 months
